RE:RE:RE:What happens if Oast does not agree?When your reputation is in the mud and have a track record of shareholder destruction, you better change your company name from AEZS first than hope you can pull the wool over new investors.
But yes the "biggest biotech" disaster in decades will make it hard for a biopharma cash burning company to raise funds on an old tired drug like Macrilen.
With CEAPRO which had (has) a stable base business that can fund it's pipeline and with potential game changing results for AV due in the fall, in the hands of a capable new CEO, it would be much easier to raise funds on its own.